We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Leukocare Licenses Biomarker Cell-Free DNA to Trillium Diagnostics

By LabMedica International staff writers
Posted on 22 Oct 2012
Leukocare AG (Munich, Germany) and Trillium Diagnostics, LLC (Brewer, Maine, USA) have formed a strategic alliance for the development and marketing of Leukocare’s method for the detection of inflammatory activity using the novel biomarker circulating cell-free DNA (cf-DNA). More...


Trillium was granted an exclusive, royalty-bearing license of Leukocare's patent and know-how for the method of measuring the quantity of cf-DNA to develop a commercial IVD assay kit for the worldwide market. Trillium will use the technology to develop an assay for the diagnosis of sepsis. The assay is expected to be approved and marketable in about 2 years’ time.

Neutrophil-derived DNA is the major component of cf-DNA, which has recently been recognized as an important predictive biomarker in severely ill patients with acute or chronic inflammatory disorders. Bruce Davis, MD, CEO and president of Trillium Diagnostics said, “cf-DNA is an important addition to our patented infection/sepsis diagnostic assays of neutrophil CD64 expression (Leuko64 assay) and soluble CD163 (Macro163 assay). We hope these three assays used in parallel will provide unparalleled sensitivity and specificity in diagnosis.”

Dr. Davis also remarked, "A prognostic assay for sepsis will represent a tremendous improvement in intensive care medicine. It clearly would fulfill an unmet medical need to help identify sepsis patients at early stage and to initiate rapid treatment actions."

Related Links:

Leukocare AG
Trillium Diagnostics, LLC



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Pipette
Accumax Smart Series
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.